Estimation of induction and maintenance costs of Infliximab, Adalimumab and Cer-tolizumab Pegol in managing Crohnʼs Disease
Brian G. Feagan(Western University), Martin C. Brown(Health Economics and Outcomes Research (United Kingdom)), Joaquín Hinojosa, Daniel G. Malone, Samuel Chin Wei Tan(Peking University)
Cited by 0
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
SCENIC International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease
|Gastroenterology|2015|765
SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease
|Gastrointestinal Endoscopy|2015|408